These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 26886220)

  • 21. Evaluating the diagnostic and prognostic value of serum TuM2-PK, NSE, and ProGRP in small cell lung cancer.
    Li L; Zhang Q; Wang Y; Xu C
    J Clin Lab Anal; 2023 Apr; 37(7):e24865. PubMed ID: 37088873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase.
    Takada M; Kusunoki Y; Masuda N; Matui K; Yana T; Ushijima S; Iida K; Tamura K; Komiya T; Kawase I; Kikui N; Morino H; Fukuoka M
    Br J Cancer; 1996 May; 73(10):1227-32. PubMed ID: 8630283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of pro-gastrin releasing peptide promotes the cell proliferation and progression in small cell lung cancer.
    Gong Z; Lu R; Xie S; Jiang M; Liu K; Xiao R; Shen J; Wang Y; Guo L
    Biochem Biophys Res Commun; 2016 Oct; 479(2):312-318. PubMed ID: 27639644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer.
    Pujol JL; Quantin X; Jacot W; Boher JM; Grenier J; Lamy PJ
    Lung Cancer; 2003 Feb; 39(2):131-8. PubMed ID: 12581564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuron-specific enolase and response to initial therapy are important prognostic factors in patients with small cell lung cancer.
    Zhou M; Wang Z; Yao Y; Zhou H; Liu M; Sun J
    Clin Transl Oncol; 2017 Jul; 19(7):865-873. PubMed ID: 28127669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Diagnostic value of ProGRP and NSE for small cell lung cancer: a meta-analysis].
    WANG J; GAO J; HE J
    Zhongguo Fei Ai Za Zhi; 2010 Dec; 13(12):1094-100. PubMed ID: 21159242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
    Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
    Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The predictive value of delta-like3 and serum NSE in evaluating chemotherapy response and prognosis in patients with advanced small cell lung carcinoma: An observational study.
    Zhu C; Huang J; Jin X; Zhang C; Zhu C; Lv M; Chen S; Du X; Feng G
    Medicine (Baltimore); 2024 Jun; 103(23):e38487. PubMed ID: 38847733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer.
    Uchida K; Kojima A; Morokawa N; Tanabe O; Anzai C; Kawakami M; Eto Y; Yoshimura K
    J Cancer Res Clin Oncol; 2002 Dec; 128(12):633-40. PubMed ID: 12474049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission.
    Muley T; Herth FJ; Heussel CP; Kriegsmann M; Thomas M; Meister M; Schneider MA; Wehnl B; Mang A; Holdenrieder S
    Tumour Biol; 2024; 46(s1):S219-S232. PubMed ID: 37840518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen.
    Niho S; Nishiwaki Y; Goto K; Ohmatsu H; Matsumoto T; Hojo F; Ohe Y; Kakinuma R; Kodama T
    Lung Cancer; 2000 Mar; 27(3):159-67. PubMed ID: 10699689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.
    Bonner JA; Sloan JA; Rowland KM; Klee GG; Kugler JW; Mailliard JA; Wiesenfeld M; Krook JE; Maksymiuk AW; Shaw EG; Marks RS; Perez EA
    Clin Cancer Res; 2000 Feb; 6(2):597-601. PubMed ID: 10690544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer.
    Lamy PJ; Grenier J; Kramar A; Pujol JL
    Lung Cancer; 2000 Sep; 29(3):197-203. PubMed ID: 10996422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pro-Gastrin-Releasing Peptide as a Marker of Small Cell Lung Cancer.
    Lyubimova NV; Kuz'minov AE; Markovich AA; Lebedeva AV; Timofeev YS; Stilidi IS; Kushlinskii NE
    Bull Exp Biol Med; 2022 Jun; 173(2):257-260. PubMed ID: 35737164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human Epididymis Protein 4 (HE4) in Patients with Small-Cell Lung Cancer.
    Wojcik E; Tarapacz J; Rychlik U; Stasik Z; Sas-Korczynska B; Skotnicki P; Kulpa JK
    Clin Lab; 2016 Sep; 62(9):1625-1632. PubMed ID: 28164590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma.
    Fizazi K; Cojean I; Pignon JP; Rixe O; Gatineau M; Hadef S; Arriagada R; Baldeyrou P; Comoy E; Le Chevalier T
    Cancer; 1998 Mar; 82(6):1049-55. PubMed ID: 9506348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology.
    Molina R; Augé JM; Bosch X; Escudero JM; Viñolas N; Marrades R; Ramírez J; Carcereny E; Filella X
    Tumour Biol; 2009; 30(3):121-9. PubMed ID: 19506400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers.
    Li BT; Lou E; Hsu M; Yu HA; Naidoo J; Zauderer MG; Sima C; Johnson ML; Daras M; DeAngelis LM; Fleisher M; Kris MG; Azzoli CG
    PLoS One; 2016; 11(1):e0146063. PubMed ID: 26730601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-6 and VEGF in small cell lung cancer patients.
    Wójcik E; Jakubowicz J; Skotnicki P; Sas-Korczyńska B; Kulpa JK
    Anticancer Res; 2010 May; 30(5):1773-8. PubMed ID: 20592377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.